R.R. KHAFIZOV¹, B.I. ZAGIDULLIN¹, N.Sh. ZAGIDULLIN², O.I. LEONTYEVA¹, A.Zh. GILMANOV², Sh.Z. ZAGIDULLIN²

¹State Emergency Clinic of Republic Tatarstan, 18 Naberezhnochelninskiy Prospekt, Naberezhnie Chelny, Russian Federation 423803

²Bashkir State Medical University, 3 Lenin St., Ufa, Russian Federation 450000

Khafizov R.R. — doctor of the Department of Roentgen-Surgical Diagnostic and Treatment Techniques, tel. +7-917-436-00-60, e-mail: radikos_h84@mail.ru¹

Zagidullin B.I. — Cand. Med. Sc., Head of the Department of Roentgen-Surgical Diagnostic and Treatment Techniques, tel. +7-917-917-55-88, e-mail: bsmp_x-ray@mail.ru¹

Zagidullin N.Sh. — D. Med. Sc., Professor of the Department of Propedeutics of Internal Diseases, tel. . +7-962-546-76-22, e-mail: znaufal@mail.ru²

Leontyeva O.I. — Head of Clinical-Diagnostic Laboratory, tel. +7-960-064-67-66, e-mail: leonteva55@mail.ru¹

Gilmanov A.Zh. — D. Med. Sc., Professor, Head of the Department of Clinical-Laboratory Diagnostics, tel. +7-927-237-55-82, e-mail: alex_gilm@yahoo.com²

Zagidullin Sh.Z. — D. Med. Sc., Professor, Head of the Department of Propedeutics of Internal Diseases, tel. +7-917-442-48-63, e-mail: zshamil@inbox.ru²

In-time diagnostics of myocardial infarction allows to stratify cardiovascular risk in patients and to determine the outcomes of acute coronary syndrome (ACS). Along with the «classical» (troponin I, TnI; Creatinine MB fraction, CK MB, myoglobin) biomarkers, recently appeared the «new» ones, such as atrial natriuretic peptide (ANP), high sensitive C-reactive protein (hsCRP) and myeloperoxidase (MPO). The research objective was to evaluate the efficacy of ANP, hsCRP and MPO in comparison with the «classical» biomarkers in patients with MI with ST elevation (STEMI). TnI was most sensitive in ACS, it was followed by CK MB and myoglobin and MPO. HsCRP and ANP showed low sensitivity. HsCRP only correlated with the level of «gold standard» diagnostics of ACS TnI and CK MB. Patients with right coronary artery occlusion had lower biomarkers level than with occlusions of other arteries. Identification of biomarkers trends in MI can lead to multi-biomarker panel construction that will increase the accuracy of ACS diagnostics and predict patients with future unfavourable cardiovascular events.

Key words: biomarker, acute coronary syndrome, acute myocardial infarction with ST-elevation, high sensitive C-reactive protein, myeloperoxidase, atrial natriuretic peptide.

 

REFERENCES

1. Alpert J.S., Thygesen K. Et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology. American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol., 2000, vol. 36, pp. 959-969.

2. Baron J.M., Lewandrowski E.L., Januzzi J.L. et al. Measurement of high-sensitivity troponin T in noncardiac medical intensive care unit patients: correlation to mortality and length of stay. Am J Clin Pathol., 2014, Apr., vol. 141 (4), pp. 488-93.

3. Lewandrowski B. Cardiac Markers of Myocardial Necrosis A History and Discussion of Milestones and Emerging New Trends. Clin Lab Med., 2014, vol. 34, pp. 31-41.

4. Squire I.B., O’Brien R.J., Demme B. Et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond), 2004, vol. 107, pp. 309-316.

5. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, vol. 102, pp. 2165-2168.

6. Anzai T., Yoshikawa T., Shiraki H. et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation, 1997, vol. 96, pp. 778-784.

7. Meuwese M.C., Stroes E.S., Hazen S.L. et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol., 2007, vol. 50, pp. 159-165.

8. Higgins J.P., Higgins J.A. Elevation of cardiac troponin I indicates more than myocardial ischemia. Clin Invest Med., 2003, vol. 26, p. 133.

9. Fox K.A., Anderson Jr. F.A., Goodman S.G. et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med., 2008, vol. 5, pp. 580-589.

10. Thygesen K., Alpert J.S., Jaffe A.S. et al. Third universal definition of myocardial infarction. J Am Coll Cardiol., 2012, vol. 60, pp. 1581-1598.

11. Ndrepepa G., Braun S., Mehilli J. et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest., 2008, vol. 38 (2), pp. 90-6.

12. Baldus S., Heeschen C., Meinertz T. et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003, 23, vol. 108 (12), pp. 1440-5.

13. Morrow D.A., Cannon C.P., Jesse R.L. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation, 2007, no. 3, vol. 115 (13), pp. 356-75.